Cyclin D1-dependent regulation of B-myb activity in early stages of neuroblastoma differentiation

被引:25
作者
Cesi, V
Tanno, B
Vitali, R
Mancini, C
Giuffrida, ML
Calabretta, B
Raschellà, G
机构
[1] ENEA, Res Ctr Casaccia, Biotechnol Unit, Sect Toxicol & Biomed Sci, I-00060 Rome, Italy
[2] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
关键词
B-myb; cyclin A; cyclin D1; neuroblastoma; differentiation;
D O I
10.1038/sj.cdd.4401103
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Levels of the transcription factor B-myb must be down-regulated to allow terminal differentiation of neuroectodermal cells and yet its constitutive expression induces early markers of neural differentiation. Thus, we investigated potential mechanisms of enhanced B-myb activity in early stages of neural differentiation. We report here that B-myb expression does not decrease, cyclin A and Sp1 levels remain constant while p21 levels increase continuously upon retinoic acid-induced differentiation of the LAN-5 neuroblastoma cell line. In contrast, cyclin D1 expression is down-regulated at the onset of the differentiative process by protein destabilization. Luciferase assays of promoter activity indicate that B-myb-dependent transactivation is enhanced in LAN-5 cells treated with retinoic acid (RA) for 24 h. The enhancement is independent from cyclin A but is suppressed by a degradation-resistant mutant form of cyclin D1. The importance of cyclin D1 in controlling B-myb activity is further suggested by co-immunoprecipitation experiments, showing that the amount of cyclin D1 co-immunoprecipitated with B-myb decreased after RA treatment. Thus, B-myb may play an active role in the early stages of differentiation when its transactivation activity is enhanced as a consequence of cyclin D1 down-modulation.
引用
收藏
页码:1232 / 1239
页数:8
相关论文
共 34 条
[1]
HUMAN NEURO-BLASTOMA CELL-LINES AS MODELS FOR THE INVITRO STUDY OF NEOPLASTIC AND NEURONAL CELL-DIFFERENTIATION [J].
ABEMAYOR, E ;
SIDELL, N .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1989, 80 :3-15
[2]
REGRESSION AND PROGRESSION IN NEUROBLASTOMA - DOES GENETICS PREDICT TUMOR BEHAVIOR [J].
AMBROS, PF ;
AMBROS, IM ;
STREHL, S ;
BAUER, S ;
LUEGMAYR, A ;
KOVAR, H ;
LADENSTEIN, R ;
FINK, FM ;
HORCHER, E ;
PRINTZ, G ;
MUTZ, I ;
SCHILLING, F ;
URBAN, C ;
GADNER, H .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) :510-515
[3]
Bies J, 1996, ONCOGENE, V12, P355
[4]
Cyclin D1 proteolysis: A retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells [J].
Boyle, JO ;
Langenfeld, J ;
Lonardo, F ;
Sekula, D ;
Reczek, P ;
Rusch, V ;
Dawson, MI ;
Dmitrovsky, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (04) :373-379
[5]
INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].
BRODEUR, GM ;
SEEGER, RC ;
BARRETT, A ;
BERTHOLD, F ;
CASTLEBERRY, RP ;
DANGIO, G ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
FREEMAN, AI ;
HAASE, G ;
HARTMANN, O ;
HAYES, FA ;
HELSON, L ;
KEMSHEAD, J ;
LAMPERT, F ;
NINANE, J ;
OHKAWA, H ;
PHILIP, T ;
PINKERTON, CR ;
PRITCHARD, J ;
SAWADA, T ;
SIEGEL, S ;
SMITH, EI ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881
[6]
Degradation of B-Myb by ubiquitin-mediated proteolysis:: involvement of the Cdc34-SCFp45Skp2 pathway [J].
Charrasse, S ;
Carena, I ;
Brondani, V ;
Klempnauer, KH ;
Ferrari, S .
ONCOGENE, 2000, 19 (26) :2986-2995
[7]
COMPARISON OF DNA ANEUPLOIDY, CHROMOSOME-1 ABNORMALITIES, MYCN AMPLIFICATION AND CD44 EXPRESSION AS PROGNOSTIC FACTORS IN NEUROBLASTOMA [J].
CHRISTIANSEN, H ;
SAHIN, K ;
BERTHOLD, F ;
HERO, B ;
TERPE, HJ ;
LAMPERT, F .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) :541-544
[8]
Glycogen synthase kinase 3β regulates cyclin D1 proteolysis and subcellular localization [J].
Diehl, JA ;
Cheng, MG ;
Roussel, MF ;
Sherr, CJ .
GENES & DEVELOPMENT, 1998, 12 (22) :3499-3511
[9]
DIMITROULAKOS J, 1994, CELL GROWTH DIFFER, V5, P373
[10]
Gomez J, 1998, J NEUROSCI RES, V51, P119, DOI 10.1002/(SICI)1097-4547(19980101)51:1<119::AID-JNR13>3.0.CO